Concurrent thalidomide and radiation therapy for extensive arterio-venous malformations

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 235-237

  Blinc, Ales ^a   Golli, Tanja ^b   Vodnik, Alenka Cerar ^c   Zver, Samo ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b Department of Obstetrics and Gynecology   (Slovenia)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

MYRIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; ARM AMPUTATION; ARTERIOVENOUS MALFORMATION; ARTERY LIGATION; ARTERY OCCLUSION; ARTICLE; ARTIFICIAL EMBOLISM; BRACHIAL ARTERY; CASE REPORT; CONSTIPATION; DROWSINESS; DRUG DOSE TITRATION; DRUG RESPONSE; ECHOCARDIOGRAPHY; ENDARTERITIS; HEMATOLOGIC DISEASE; HUMAN; LIMB ISCHEMIA; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE;

ANGIOGENESIS INHIBITORS; ARM; ARTERIOVENOUS MALFORMATIONS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; THALIDOMIDE; THORACIC ARTERIES; TREATMENT OUTCOME; VEINS;

EID: 38349099204     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0396     Document Type: Article

References (29)

1. D'Amato R, Loughnan M, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
2. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14-19.
3. Brouillard F, Vikkula M. Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 2003; 63: 340-351.
4. Lee BB. Advanced management of congenital vascular malformations (CVM). Int Angiol 2002; 21: 209-213.
5. Lee BB, Do YS, Yakes W, et al. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg 2004; 39: 590-600.
6. Lee BB. Critical issues in management of congenital vascular malformations. Ann Vasc Surg 2004; 18: 380-392.
7. Al-Shahi R, Warlow C. A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain 2001; 124: 1900-1926.
8. Jeong HS, Baek CH, Son YI, et al. Treatment of extracranial arteriovenous malformations of the head and neck. Acta Otolaryngol 2006; 126: 295-300.
9. Plowman PN. Radiation therapy for vascular malformations - a changing scene. Clin Oncol 2002; 14: 91-96.
10. Andrade-Souza YM, Ramani M, Scora D, et al. Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery 2007; 60: 443-452.
11. Kilic K, Konya D, Kurtkaya O, et al. Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. J Neurosurg 2007; 106: 463-469.
12. Hanze J, Weissmann N, Grimminger F, et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-787.
13. Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in arigiogenesis. Thromb Haemost 2007; 97: 355-363.
14. Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost. 2007; 97: 755-762.
15. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
16. Belo AV, Leles F, Barcelos, et al. Murine chemokine CXCL2/KC is a surrogate marker for angiogenic activity in the inflammatory granulation tissue, Microcirculation 2005; 12: 597-606.
17. Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
18. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-114.
19. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias, Am J Gastroenterol 2003; 98: 221-222.
20. Kirkham SE, Lindley KJ, Elawad MA, et al. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-587.
21. Bauditz J, Lochs H, Voderbolzer W. Macroscopic appearance of intestinal angiodysplasias under anti-angiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-1039.
22. Heidt J, Langers AM, van der Meer FJ, et al. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-428.
23. Pérez-Encinas M, Rabuñal Martínez MJ, Bello Lopez JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002; 87: ELT34.
24. Bauditz J, Schachschal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-612.
25. Hussein MA. Thromboembolism risk reduction in multiple rayeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
26. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-1036.
27. Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis 2007; epub ahead of print.
28. Altintas A, Ayyildiz O, Atay AE, et al. Thalidomide-associated arterial thrombosis: two case reports. Ann Acad Med Singapore 2007; 36: 304-306.
29. The Cleveland Clinic multiple Myeloma Research Center. Safety and tolerability of thalidomide. Available at: http://www.clevelandclinic.org/myeloma/safety_of_thalidomide.htm.